Antithrombin Panel

Also known as: AT3 PAN

Clinical Use

Use

The Antithrombin Panel is utilized to detect and subtype antithrombin deficiency, which may be associated with hereditary thrombophilia and a risk for hypercoagulability. This panel measures both antithrombin enzymatic activity and antigen levels, providing a comprehensive assessment for diagnosing inherited antithrombin deficiency. The test may help in identifying patients at risk of thrombosis when acquired conditions are excluded, and in such cases, may prompt further evaluation or repeat testing.

Special Instructions

Not provided.

Limitations

The tests within the Antithrombin Panel may produce artifactually altered results if the patient is under direct thrombin inhibitors or other anticoagulant therapies. Such medications need to be considered and excluded when interpreting test results. The enzymatic activity of antithrombin may be decreased due to liver disease, acute thrombosis, disseminated intravascular coagulation (DIC), heparin therapy, or asparaginase therapy, among other causes. The antigen level assessment serves to differentiate between type I and type II deficiencies; however, a low antigen or activity level alone is not definitive for diagnosing hereditary deficiency without excluding acquired causes.

Test Details

New York Approved